Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L. Kurland L, et al. Among authors: malmqvist k. J Hypertens. 2002 Apr;20(4):657-63. doi: 10.1097/00004872-200204000-00023. J Hypertens. 2002. PMID: 11910301 Clinical Trial.
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L. Kurland L, et al. Among authors: malmqvist k. Am J Hypertens. 2002 May;15(5):389-93. doi: 10.1016/s0895-7061(02)02256-2. Am J Hypertens. 2002. PMID: 12022239 Clinical Trial.
Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F, Malmqvist K, Ohman KP, Kahan T. Nyström F, et al. Among authors: malmqvist k. J Hypertens. 2002 Aug;20(8):1527-33. doi: 10.1097/00004872-200208000-00015. J Hypertens. 2002. PMID: 12172314 Clinical Trial.
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Hallberg P, Lind L, Michaëlsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H. Hallberg P, et al. Among authors: malmqvist k. J Hypertens. 2003 Mar;21(3):621-4. doi: 10.1097/00004872-200303000-00029. J Hypertens. 2003. PMID: 12640257 Clinical Trial.
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L. Kurland L, et al. Among authors: malmqvist k. Am J Hypertens. 2004 Jan;17(1):8-13. doi: 10.1016/j.amjhyper.2003.09.009. Am J Hypertens. 2004. PMID: 14700505 Clinical Trial.
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P, Lind L, Billberger K, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H. Hallberg P, et al. Among authors: malmqvist k. Clin Cardiol. 2004 Mar;27(3):169-73. doi: 10.1002/clc.4960270315. Clin Cardiol. 2004. PMID: 15049387 Free PMC article. Clinical Trial.
82 results